에 대한 최신 뉴스 Exact Sciences (NASDAQ:EXAS) 주식

Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Large Cap

News

Movers

ARWR

CPRT

ESTC

EXAS

MRNA

RIVN

RKLB

SNAP

SRPT

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주식이 22.06% 급등했다. 이는 회사가 66억 달러의 에너지부(DOE)의 대출 약정을 확보한 후 발생한 일이다.

리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)

Biotech

Earnings

After-Hours Center

이그젝트 사이언스(NASDAQ:EXAS) 주가는 화요일(5일) 장 마감 이후 3분기 실적을 발표한 후 하락하고 있다. 실적 관련해 자세한 내용을 살펴보자. 실적 세부 사항: 이그젝트 사이언스의 분기 기준 GAAP 주당순손실은 21센트로 애널리스트 컨센서스 예상치 주당순손실 20센트를 하회했다. 분기 매출은 7억 900만 달러로 컨센서스 예상치 7억 1,766만 달러에 미치지 못했다. 

이그젝트 사이언스, 부진한 3분기 실적 발표 이후 30% 가까이 급락, 연간 지침 예상치 하회

$BTC

AVGO

BNTX

CHWY

FSLR

MSTR

ORCL

ROKU

SMMT

WOOF

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식은 회사가 $2억 3,500만의 순수익을 올렸다고 발표한 후 98.32% 급등했다.

츄이, 브로드컴 및 ARM은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 8일-9월 14일)

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exasol AG

B of A Securities analyst Derik De Bruin maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $75 to $72.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Exact Sciences, Lowers Price Target to $72

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares jumped 22.06% after securing a<a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener"> $6.6 billion DOE loan commitment</a>.</li>
<li>Rocket Lab USA, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock surged 21.73% after it secured a $23.9 million CHIPS Act grant to enhance its <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">semiconductor operations in New Mexico</a>.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock upped 20.67% after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) for <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">multiple clinical and preclinical siRNA programs</a>.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock increased 16.98%. The Centers for Medicare &amp; Medicaid Services posted final payment determinations for its <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025 Clinical Laboratory Fee Schedule</a>.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares rose 16.29%. Wedbush Securities analyst Daniel Ives has significantly increased his optimism on the next phase of the AI revolution, focusing on its <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">transformative impact on the software sector</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares upped 14.13%. Citigroup analysts raised the<a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast on the stock</a>.</li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) <a href="https://www.benzinga.com//node/42197195" target="_blank" rel="noreferrer noopener">shares surged 12.58%</a> last week.</li>
<li>Ralph Lauren Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) stock gained 11.72% last week.</li>
<li>Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) stock was up 11.41% after the company reported better-than-expected Q1 sales results.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) stock increased 12.18%. Citigroup analysts raised the <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
</ol>
Photo by rblfmr via Shutterstock

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

Editor&#8217;s note: The headline of this story was updated to correct an error related to the reported day of the week.
On Monday, the Centers for Medicare &amp; Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Included was a final decision related to CMS pricing for Exact Sciences Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) Cologuard Plus, a second-generation test that received FDA <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">approval in October</a>.
William Blair writes that the <a target="_blank" href="https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/annual-public-meetings" rel="noreferrer noopener">determinations</a> effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41776963/colorectal-cancer-diagnostic-focused-exact-sciences-stock-plunges-on-weak-annual-gu" rel="noreferrer noopener">Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point</a>
The determination reverses the September preliminary decision but aligns with a proposal made during the public comment period.
The analyst writes that reimbursement for Cologuard Plus will now be calculated based on two components: three times the fee for methylation analysis of Septin-9 ($192 x 3) and the fee for a FIT test ($15.92).
This pricing adjustment is expected to take effect for Medicare volumes when the test officially launches in late first quarter or early second quarter of 2025. Medicare fee-for-service volumes should reflect the new pricing immediately upon launch, with Medicare Advantage following soon after.
The company is also likely to renegotiate commercial contracts for higher pricing, which may gradually roll out over the coming quarters and years.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a>
The analyst highlights that the update is a positive outcome for the company, as it simplifies the process of implementing a price increase compared to the more complex advanced diagnostic laboratory test (ADLT) pathway.
From a financial perspective, this decision is expected to support a moderate pricing boost starting in 2025. Based on William Blair&#8217;s estimates, this could add at least 300 basis points to Cologuard's growth rate next year, which is projected to be around 15% overall.
Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42177702/exact-sciences-advances-breast-cancer-care-with-the-oncotype-dx-test-and-genomic-profiling-researc" rel="noreferrer noopener">scheduled next month</a>.
Price Action: EXAS stock is up 7.60% at $59.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42190381/analog-devices-q4-earnings-beats-estimates-automotive-rebound-outlook" target="_blank" rel="noreferrer noopener">Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook &amp; More</a></li>
</ul>
Illustration of Phrama lab worker created with MidJourney.

Analyst Color

Equities

Health Care

Reiteration

Trading Ideas

General

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

19 analysts have shared their evaluations of Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $75.37, a high estimate of $95.00, and a low estimate of $60.00. A 3.95% drop is evident in the current average compared to the previous average price target of $78.47. 
<img src="https://www.benzinga.com/files/images/story/2024/1732644078_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exact Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Nowark</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Exact Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exact Sciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Exact Sciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Get to Know Exact Sciences Better</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Exact Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.78% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exact Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.4%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 19 Analyst Ratings Have To Say About Exact Sciences

TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $82 to $86.

TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $86

BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $65 to $75.

BTIG Maintains Buy on Exact Sciences, Raises Price Target to $75

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) rose sharply during Tuesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance with its <a href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more">midpoint above estimates.</a>
Smucker shares surged 6.2% to $120.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 59% to $7.55 after the company reported better-than-expected third-quarter sales results.</li>
<li>Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) gained 30.2% to $18.76 after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) surged 22.8% to $4.1750 after the company announced its board approved an amendment for a dividend policy to increase the payout ratio. Also, the company reported third-quarter financial results.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) gained 20.3% to $64.32 as the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its midpoint above estimates.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 18.1% to $22.17 after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.</li>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares rose 15% to $25.65.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) gained 13.8% to $1.8450.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 12.6% to $2.1850.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) surged 12.2% to $4.77. POET Technologies recently announced plans to expand its capacity.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares gained 9.1% to $125.10 after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA programs.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) gained 8% to $99.21 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $93 to $113.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) surged 7.8% to $59.45. The company announced it will present 10 abstracts at SABCS.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) surged 7.4% to $192.62 after the company reported better-than-expected fourth-quarter EPS and sales.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 7.3% to $25.82.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 5.8% to $8.94. UBS analyst Jay Sole upgraded Hanesbrands from Neutral to Buy and raised the price target from $9 to $11.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42190113/starbucks-to-rally-around-13-here-are-10-top-analyst-forecasts-for-tuesday">Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Intraday Update

Markets

EMBC

HSAI

NGNE

POET

SGMO

SMRT

SMTC

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

WIIM

Exact Sciences shares are trading higher. The company announced it will present 10 abstracts at SABCS.

U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.&#8217;s largest trading partners &#8211; Canada and Mexico &#8211; with tariffs.
The Dollar Index strengthened and was hovering around the 107 level. Expectations of a further 25 basis point rate cut in December have fallen to just 59% now, down from 75% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group's FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.08%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.09%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.07%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.26%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.06% to $597.87 and the Invesco QQQ ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NYSE">QQQ</a>) rose 0.04% to $506.80, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The Dow Jones closed higher by around 440 points to 44,736.57 on Monday. The S&amp;P 500 rose 0.30% to 5,987.37, while the Nasdaq Composite rose 0.27% to close at 19,054.84 during Monday&#8217;s session.
On the economic data front, the Chicago Fed National Activity Index fell to -0.40 in October compared to -0.27 in the previous month and versus market estimates of -0.20.
The Dallas Fed&#8217;s Texas manufacturing activity index rose to -2.7 in November compared to a reading of -3 in the previous month and versus market estimates of -2.4.
Most sectors on the S&amp;P 500 closed on a positive note, with real estate, materials, and consumer discretionary stocks recording the biggest gains on Monday.
However, energy and information technology stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.27%</td>
<td>19,054.84</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.30%</td>
<td>5,987.37</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.99%</td>
<td>44,736.57</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.47%</td>
<td>2,442.03</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
&#8220;Equity markets continue to display remarkable strength. The S&amp;P 500 and other major indices are flirting with or surpassing all-time highs. The breadth of the rally is particularly noteworthy, with a growing number of stocks hitting 52-week highs,&#8221; said Jeremy Siegel, a senior economist <a href="https://resources.wisdomtree.com/weekly-siegel-commentary/">at</a> WisdomTree.
&#8220;This breadth is a key signal of market health, as it indicates a robust and inclusive rally rather than one concentrated in a few mega-cap names,&#8221; he added.
Analysts at BlackRock <a href="https://www.blackrock.com/us/individual/insights/blackrock-investment-institute/weekly-commentary">said</a> that they are positive about the AI theme in the technology sector. &#8220;Valuations for AI beneficiaries are supported as tech companies keep beating high earnings expectations. We think upbeat sentiment can broaden out,&#8221; their note said.
BlackRock also added that they see the AI buildout and adoption creating opportunities across sectors. &#8220;We get selective, moving toward beneficiaries outside the tech sector. Broad-based earnings growth and a quality tilt make us overweight U.S. stocks overall.&#8221;
Predicting how December could look like for the stock markets, Ryan Detrick, chief market strategist at Carson Group, highlighted how markets have performed better than average in December in every election year since 1950.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No month is more likely to be higher than December in an election year (83.3%). <a href="https://t.co/WrOI59tUiR">pic.twitter.com/WrOI59tUiR</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1861092399449284637?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data:
This week&#8217;s economic calendar is not as packed as last week&#8217;s due to Thanksgiving. Here are the key events lined up for Tuesday:
<ul>
<li>The S&amp;P Case-Shiller home price index for 20 cities will be released at 9 a.m. ET.</li>
<li>Data on consumer confidence and new home sales will be released at 10 a.m. ET.</li>
<li>The minutes of the Fed's November FOMC meeting will be released at 2 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Woodward Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is up by almost 11% in premarket trading after Pathstone Holdings LLC boosted its position by 28.6% during the 3rd quarter, as per SEC filing. The company also reported a record revenue of $3 billion in the September quarter, aided by the performance in both aerospace and industrial segments.</li>
<li>Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) rose 6% in premarket as it reacted to reports that Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reached a "conditional" settlement concerning a 2020 lawsuit. The Elon Musk-led company had accused Rivian of poaching Tesla employees to get ahold of its EV trade secrets.</li>
<li>Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) was trading above 5.5% in premarket after the company advanced breast cancer care with the Oncotype DX test and genomic profiling research at the San Antonio Breast Cancer Symposium 2024.</li>
<li>Semtech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) was up over 19% in premarket hours after the chipmaker reported a strong set of earnings. The company posted revenue of $236.8 million for the quarter with quarterly earnings of $0.26 per share as compared to $0.02 per share a year ago.</li>
<li>Blue Bird Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was down over 10% in premarket after its fourth-quarter earnings missed analyst estimates. The quarterly earnings of $0.77 per share missed the Zacks Consensus Estimate of $0.78 per share. This compares to the EPS of $0.66 in Q4 of the previous fiscal.</li>
<li>Investors are awaiting earnings results from Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>), and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.93% to hover around $69.57.
The 10-year Treasury note yield eased to 4.293%.
Major Asian markets ended lower on Tuesday, except for Hong Kong&#8217;s Hang Seng Index. European markets were also down in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo courtesy: Wikimedia

Economics

Federal Reserve

Pre-Market Outlook

BLBD

DELL

TSLA

US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks

The company said new data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally.

Exact Sciences To Present 10 Abstracts Demonstrating Breadth Of Its Precision Oncology Portfolio At SABCS

New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective
Modeling data estimate adding MCED testing to standard-of-care screening could reduce cancer mortality by 17%
New analysis from DETECT-A study supports MCED testing as a complement to current guideline-recommended screening
Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening may reduce the incidence of stage IV cancer and, subsequently, cancer mortality over 10 years. Another new analysis from the DETECT-A study suggests that adding MCED testing complements guideline-recommended lung cancer screening without affecting adherence to current standard of care. These findings will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Liquid Biopsy from November 13-16, 2024, in San Diego, Calif.

Exact Sciences Unveils Data Showing Multi-Cancer Early Detection At AACR Special Conference On Liquid Biopsy; New Evidence Shows Multi-Biomarker Class Approach Improved Cancer Detection, Including In Earlier Stages When Treatment May Be More Effective; Modeling Data Estimate Adding MCED Testing To Standard-Of-Care Screening Could Reduce Cancer Mortality By 17%

Insider Trades

Exact Sciences CEO Kevin Conroy Buys 19,500 Shares At $51.35 Each, Investing $1M; Now Holds 1.07M Direct Shares, With Total Holdings Reaching 1.41M Shares Plus 683K Options And Restricted Stock Units

Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $85 to $75.

Piper Sandler Maintains Overweight on Exact Sciences, Lowers Price Target to $75

Citigroup analyst Patrick Donnelly maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $80 to $75.

Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $75

Jefferies analyst Brandon Couillard maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $84 to $85.

Jefferies Maintains Buy on Exact Sciences, Raises Price Target to $85

BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $65.

BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $65

Stifel analyst Daniel Arias maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $67.

Stifel Maintains Buy on Exact Sciences, Lowers Price Target to $67

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $95 to $75.

Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $75

TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $90 to $82.

TD Cowen Maintains Buy on Exact Sciences, Lowers Price Target to $82

Goldman Sachs analyst Matthew Sykes maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $75 to $65.

Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $65

Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Veracyte: Getting Frothy

In a report released today, Daniel Brennan from TD Cowen maintained a Buy rating on Exact Sciences (EXAS – Research Report). The company's shares c...

Exact Sciences (EXAS) Gets a Buy from TD Cowen

10 BofA U.S. options overwriting ideas

BofA lowered the firm's price target on Exact Sciences (EXAS) to $72 from $75 and keeps a Buy rating on the shares. The Life Sciences Tools sector ...

Exact Sciences price target lowered to $72 from $75 at BofA

Exact Sciences: Profitability Remains Elusive

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exact Sciences (EXAS – Research Report), Neurocrine ...

Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), Neurocrine (NBIX)

Hartford Healthcare Fund Q3 2024 Commentary

Voya SmallCap Opportunities Portfolio Q3 2024 Commentary

Voya Small Cap Growth Strategy Q3 2024 Commentary

CHDN

CMSA

CMSC

CMSD

DXCM

HSRT

ISRG

MEMS

MODV

NBIX

SIMO

SITM

VCYT

VRTX

Screenshot 2024-08-30 at 6.27.59 PM

MYNZ

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Screenshot 2024-06-04 at 5.31.42 PM

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Press Releases

Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

Exact Sciences Schedules Third Quarter 2024 Earnings Call

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

Exact Sciences to Participate in November Investor Conference

Exact Sciences Announces Third-Quarter 2024 Results

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

Exact Sciences to Participate in December Investor Conferences

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

B of A Securities

TD Cowen

BTIG

Piper Sandler

Citigroup

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 22.06% 급등했다. 이는 회사가 <a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener">66억 달러의 에너지부(DOE)의 대출 약정</a>을 확보한 후 발생한 일이다.
2. 로켓랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">뉴멕시코 주에서 반도체 운영을 강화하기 위한 2,390만 달러의 칩스(CHIPS) 법안 지원금</a>을 확보한 후 21.73% 상승했다.
3. 사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주식이 20.67% 상승했다. 이는 회사가 애로우헤드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>)와 <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">여러 임상 및 비임상 siRNA 프로그램</a>에 대한 글로벌 라이선스 및 협력 계약을 발표한 후 발생한 일이다.
4. 이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)의 주식이 16.98% 상승했다. 이는 메디케어 및 메디케이드 서비스 센터가 <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025년 임상 실험실 수수료 일정</a>에 대한 최종 지급 결정을 발표한 후 발생한 일이다.
5. 엘라스틱 N.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>)의 주식이 16.29% 상승했다. 웨드부시 증권의 애널리스트인 댄 아이브스가 인공지능(AI) 혁명의 다음 단계에 대한 낙관론을 크게 높인 후 발생한 일이다. 그는 소프트웨어 분야에 대한 <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">변혁적 영향을 강조</a>했다.
6. 울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)의 주식이 14.13% 상승했다. 이는 씨티그룹의 애널리스트들이 주식의 <a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정</a>한 후 발생한 일이다.
7. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식이 지난 주 12.58% 급등했다.
8. 랄프 로렌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)의 주식이 지난 주 11.72% 상승했다.
9. 코파트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>)의 주식은 회사가 예상보다 좋은 1분기 매출 실적을 발표한 후 11.41% 상승했다.
10. 스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>)의 주식이 12.18% 상승했다. 이는 씨티그룹의 애널리스트들이 주식의 <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정</a>한 후 발생한 일이다.
사진 출처: rblfmr via Shutterstock

이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ" target="_blank" rel="noopener">EXAS</a>) 주가는 화요일(5일) 장 마감 이후 3분기 실적을 발표한 후 하락하고 있다. 실적 관련해 <a href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results" target="_blank" rel="noopener">자세한 내용을 살펴보자.</a>
실적 세부 사항: 이그젝트 사이언스의 분기 기준 GAAP 주당순손실은 21센트로 애널리스트 컨센서스 예상치 주당순손실 20센트를 하회했다. 분기 매출은 7억 900만 달러로 컨센서스 예상치 7억 1,766만 달러에 미치지 못했다.
케빈 콘로이(Kevin Conroy) 이그젝트 사이언스 CEO는 다음과 같이 말했다.
&#8220;이그젝트 사이언스 팀은 플랫폼을 강화하고 비즈니스를 효율적으로 성장시키면서 암 퇴치를 돕고 있다. 3분기에 우리는 그 어느 때보다 많은 환자에게 검사 결과를 제공하고 수익성을 개선했으며, 혁신적인 암 진단 파이프라인에서 주요 이정표를 달성했다. 진전이 있었지만 3분기 실적 및 업데이트된 연간 전망은 우리의 잠재력을 충분히 반영하지 못했다. 우리는 2025년에 성장을 가속화할 계획이며, 장기적인 전망은 여전히 강력하다.&#8221;
전망: 향후 전망과 관련해 이그젝트 사이언스는 2024회계연도 총 매출을 27억 3천만 달러~27억 5천만 달러 범위로 예상했으며 이는 예상치 28억 3천만 달러를 하회하는 수준이다.
이그젝트 사이언스 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noopener">벤징가 프로</a>에 따르면, 화요일 애프터마켓에서 27.87% 하락한 50.15달러에서 거래되고 있다.
더 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41719896/alibaba-layoffs-hit-metaverse-division-will-the-chinese-e-commerce-giant-double-down-on-ai" target="_blank" rel="noopener">알리바바, 메타버스 부문 대규모 정리해고: AI 투자 강화할까?</a></li>
</ul>
사진: 이그젝트 사이언스 제공
벤징가 프로의 독점 뉴스 및 도구를 활용해 수익률을 높이세요. 다른 트레이더보다 더 빠르게 앞서갈 수 있습니다. 
14일 무료 체험을 시작하려면 <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하세요!

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40833208" target="_blank" rel="noreferrer noopener">$2억 3,500만</a>의 순수익을 올렸다고 발표한 후 98.32% 급등했다.
2. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식은 GSK가 단순 포진 바이러스 백신 개발을 중단하자 모더나와 바이오엔텍와 같은 다른 경쟁자들에게 길을 열어주면서 지난주 31.77% 상승했다.
3. 앱러빈 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/app/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 올린 후</a> 28.38% 상승했다.
4. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식은 펫코 헬스 앤 웰니스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>)의 <a href="https://www.benzinga.com//node/40822147" target="_blank" rel="noreferrer noopener">재무 결과 발표</a>에 동조하는 분위기 속에서 21.37% 상승했다.
5. 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)의 주식은 일부 반도체 주식의 <a href="https://www.benzinga.com//node/40852990" target="_blank" rel="noreferrer noopener">반등</a>으로 인해 20.81% 상승했다.
6. Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주식은 레이먼드 제임스(Raymond James)가 주식을 아웃퍼폼(Outperform) 등급으로 분석을 시작하고 <a href="https://www.benzinga.com/quote/arm/analyst-ratings" target="_blank" rel="noreferrer noopener">$160의 목표 주가</a>를 발표한 후 20.50% 상승했다.
7. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 회사가 18,300개의 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)을 구매했다고 발표한 후 18.74% 상승했다.
8. 킨로스 골드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener">그레이트 베어(</a><a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Great Bear</a><a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener">) 프로젝트</a>에 대한 초기 경제 평가를 완료했다고 발표한 후 17.14% 상승했다.
9. 워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주식은 최근 발표된 차터(Charter)와의 다년간 파트너십으로 인해 지난주 17.10% 상승했다. 이 파트너십은 선형 비디오와 스트리밍 서비스를 통합하여 비디오 번들의 유연성과 가치를 향상시킨다.
10. 버티브 홀딩스, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)의 주식은 17.02% 상승했다.
이미지 출처: Chewy
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)가 예상보다 나은 2분기 재무 결과를 보고하고 <a class="ticker" href="https://www.benzinga.com//node/40085338" target="_blank" rel="noreferrer noopener">트윈스트랜드 바이오사이언스(TwinStrand Biosciences)</a>와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/exas/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측</a>을 하향 조정했다.</li>
<li>앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)가 예상보다 나은 2분기 재무 실적을 발표한 후 주가는 15.35% 상승했다. 애널리스트들은 각자의 <a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>레즈메드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>)의 주가는 예상보다 나은 4분기 실적을 보고하고 <a href="https://www.benzinga.com//node/40133504" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 배당금을 인상</a>한 후 10.09% 상승했다. 몇몇 분석가들도 주식 가격 예측을 높였다.</li>
<li>코카콜라 콘솔리데이티드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>)의 주가는 회사가 2분기 재무 실적이 <a href="https://www.benzinga.com//node/40081001" target="_blank" rel="noreferrer noopener">전년 대비 증가</a>했다고 보고한 후 12.21% 상승했다.</li>
<li>덱스콤(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)의 주식은 지난주 11.18% 상승하여, 52주 최저점에서 반등했다.</li>
<li>스프라우츠 파머스 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)의 주가는 회사가 예상보다 나은 2분기 재무 실적을 보고하고 예상치를 웃도는 3분기 실적 가이던스를 발표한 후 11.87% 상승했습니다. 많은 분석가들이 회사의 <a href="https://www.benzinga.com//node/40048771" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가</a>를 높였다.</li>
<li>UL 솔루션즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>)가 <a href="https://www.benzinga.com//node/40063544" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 재무 실적</a>을 발표한 후 주가는 11.74% 상승했다.</li>
<li>랩코프 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>)의 주가는 예상보다 나은 2분기 재무 실적을 보고하고 FY24 매출 가이던스를 예상치보다 높인 후 11.34% 상승했다. 몇몇 분석가들은 회사에 대한 <a href="https://www.benzinga.com//node/40135030" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 예측</a>을 높였다.</li>
<li>C.H. 로빈슨 월드와이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>)의 주가는 예상보다 나은 2분기 조정 EPS 실적을 발표한 후 10.98% 상승했다. 다수의 기업도 각각의 <a href="https://www.benzinga.com/quote/chrw/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>도어대시(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>)가 <a href="https://www.benzinga.com//node/40116158" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 매출</a>을 보고한 후 주가는 10.24% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 높였다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%eb%a7%88%ec%9d%b4%ed%81%ac%eb%a1%9c%ec%8a%a4%ed%8a%b8%eb%a0%88%ed%8b%b0%ec%a7%80-%eb%b0%8f-%ec%9d%b8%ed%85%94%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc/" target="_blank" rel="noopener">마이크로스트레티지 및 인텔은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 28일-8월 3일</a><a href="https://www.benzinga.com/news/24/08/40150484/microstrategy-intel-and-moderna-are-among-top-12-large-cap-losers-last-week-july-28-august-3-are-the">)</a></li>
</ul>
사진 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ALNY

CHRW

COKE

CVNA

DASH

PYPL

도어대시와 이그젝트 사이언스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 28일-8월 3일)

이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)의 주가는 회사가 수요일 2분기 재무 결과를 발표한 후 급등했다. 보고서의 <a href="https://www.benzinga.com/pressreleases/24/07/b40080650/exact-sciences-announces-second-quarter-2024-results">세부 사항</a>은 다음과 같다.
주요 정보: 대장암 조기발견 및 예방에 초점을 둔 분자진단 회사인 이그젝트 사이언스(Exact Sciences)는 분기별 주당 손실을 9센트로 보고했는데, 이는 분석가들의 합의된 손실 추정치인 32센트를 71.88%나 앞선 것이다.
이 회사는 분기별 매출이 6억 9,926만 4,000달러로 분석가 합의 추정치인 6억 9,000만 3,000달러를 상회했으며 지난해 같은 기간보다 매출이 12.41% 증가했다고 보고했다. 스크리닝 매출은 15% 증가한 5억 3,200만 달러였으며, 정밀 종양학(Precision Oncology) 매출은 6% 증가한 1억 6,800만 달러였다.
이그젝트 사이언스는 분기 동안 처음으로 콜로가드(Cologuard)를 사용하여 100만 명 이상의 사람들을 검사했으며 온코타입(Oncotype) DX를 사용하여 기록적인 수의 암 환자를 테스트했다고 밝혔다.
또한 회사는 무세포 핵산 서열 분석 분야의 특허 재산에 대해 트윈스트랜드 바이오사이언스(TwinStrand Biosciences)와 독점 <a href="https://www.benzinga.com/pressreleases/24/07/n40080659/twinstrand-biosciences-and-exact-sciences-announce-exclusive-license-agreement-for-duplex-sequenci">라이선스 계약</a>을 발표했다.
회장 겸 CEO인 케빈 콘로이(Kevin Conroy)는 &#8220;우리의 2분기 결과는 이그젝트 사이언스의 세계적 수준의 팀의 헌신과 우리 고유의 플랫폼의 힘을 보여준다&#8221;고 말했다. "우리는 그 어느 때보다 더 많은 환자와 의료 전문가에게 답변을 제공하고 기록적인 매출과 수익성을 달성했으며 각 주요 파이프라인 프로그램을 발전시켰다. 추진력은 계속해서 형성되어 암 근절을 돕겠다는 우리의 목적에 힘을 실어주고 있다."
전망: 이그젝트 사이언스는 2.81조 ~ 2.85조 달러 사이의 연간 매출 가이던스 (애널리스트 예상치 2.829조 달러 대비)를 유지했다.
EXAS 주가 움직임: 이그젝트 사이언스의 주식은 수요일 시간외 거래에서 12.24% 상승한 51.27달러를 기록했다.
이미지: Exact Sciences Corporation 제공
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이그젝트 사이언스: 강력한 제2분기 순이익과 매출 발표 후 시간외 거래에서 주가 급등

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

Comments

Exact Sciences

뉴스

에 대한 최신 뉴스 Exact Sciences (NASDAQ:EXAS) 주식

일요일, 12월 01, 2024

수요일, 11월 06, 2024

일요일, 9월 15, 2024

일요일, 8월 04, 2024

목요일, 8월 01, 2024

화요일, 6월 11, 2024

금요일, 6월 07, 2024

목요일, 5월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌